Yarrow Bioscience, Inc. SEC filings YARW
Yarrow Bioscience, Inc. has 682 filings in SEC EDGAR's recent list, going back to Jan 7, 2013. Its latest annual report, Form ARS, was filed on Jun 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 19, 2026 | — |
| 425 | Filing | Jul 14, 2026 | — |
| 425 | Filing | Jul 10, 2026 | — |
| EFFECT | Filing | Jun 15, 2026 | — |
| DRS | Filing | Jan 30, 2026 | — |
| 425 | Filing | Jan 30, 2026 | — |
| 425 | Filing | Dec 17, 2025 | — |
| EFFECT | Filing | Mar 14, 2024 | — |
| CORRESP | Letter to the SEC | Mar 12, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2024 | — |
| EFFECT | Filing | Nov 22, 2023 | — |
| CORRESP | Letter to the SEC | Nov 20, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 17, 2023 | — |
| D | Filing | Nov 16, 2023 | — |
| D | Filing | Nov 18, 2022 | — |
| EFFECT | Filing | May 14, 2021 | — |
| CORRESP | Letter to the SEC | May 11, 2021 | — |
| UPLOAD | Letter from the SEC | May 10, 2021 | — |
| 425 | 8-k | Feb 6, 2020 | — |
| 425 | 8-k | Jan 28, 2020 | — |
| 425 | Filing | Jan 16, 2020 | — |
| 425 | Filing | Jan 16, 2020 | — |
| 425 | 8-k | Jan 15, 2020 | — |
| EFFECT | Filing | Jan 7, 2020 | — |
| CORRESP | Letter to the SEC | Jan 6, 2020 | — |
| 425 | Filing | Dec 20, 2019 | — |
| 425 | 8-k | Dec 16, 2019 | — |
| 425 | Filing | Dec 9, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2019 | — |
| 425 | 8-k | Dec 4, 2019 | — |
| 425 | Filing | Nov 21, 2019 | — |
| 425 | Filing | Nov 12, 2019 | — |
| 425 | Filing | Nov 12, 2019 | — |
| 425 | 8-k | Nov 12, 2019 | — |
| 425 | 8-k | Nov 12, 2019 | — |
| EFFECT | Filing | Feb 12, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| CT ORDER | Filing | Jan 26, 2018 | — |
| EFFECT | Filing | Jan 24, 2018 | — |
| CORRESP | Letter to the SEC | Jan 22, 2018 | — |
| CORRESP | Letter to the SEC | Jan 22, 2018 | — |
| CORRESP | Letter to the SEC | Jan 22, 2018 | — |
| CORRESP | Letter to the SEC | Jan 22, 2018 | — |
| CORRESP | Letter to the SEC | Jan 19, 2018 | — |
| CORRESP | Letter to the SEC | Jan 19, 2018 | — |
| CERT | Filing | Jan 19, 2018 | — |
| 8-A12B | Filing | Jan 19, 2018 | — |
| CORRESP | Letter to the SEC | Jan 19, 2018 | — |
| CORRESP | Letter to the SEC | Jan 18, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 17, 2018 | — |
| CORRESP | Letter to the SEC | Jan 5, 2018 | — |
| CORRESP | Letter to the SEC | Jan 4, 2018 | — |
| CORRESP | Letter to the SEC | Dec 28, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2017 | — |
| DRS/A | Filing | Dec 5, 2017 | — |
| DRSLTR | Filing | Dec 4, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2017 | — |
| DRS | Filing | Oct 30, 2017 | — |
| DRSLTR | Filing | Oct 30, 2017 | — |
| D | Filing | Jul 28, 2017 | — |
| D | Filing | Jan 7, 2013 | — |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- YARW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1566044
- Former names
- VYNE Therapeutics Inc. (until Jul 24, 2026); Menlo Therapeutics Inc. (until Sep 2, 2020); Menlo Therapeutics, Inc. (until Jan 31, 2018); Tigercat Pharma, Inc. (until Jan 7, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.